@article{e3b1409191ea49c984a35585008709da,
title = "Report of consensus panel 7 from the 11th international workshop on Waldenstr{\"o}m macroglobulinemia on priorities for novel clinical trials",
abstract = "Recent advances in the understanding of Waldenstr{\"o}m macroglobulinemia (WM) biology have impacted the development of effective novel agents and improved our knowledge of how the genomic background of WM may influence selection of therapy. Consensus Panel 7 (CP7) of the 11th International Workshop on WM was convened to examine the current generation of completed and ongoing clinical trials involving novel agents, consider updated data on WM genomics, and make recommendations on the design and prioritization of future clinical trials. CP7 considers limited duration and novel-novel agent combinations to be the priority for the next generation of clinical trials. Evaluation of MYD88, CXCR4 and TP53 at baseline in the context of clinical trials is crucial. The common chemoimmunotherapy backbones, bendamustine-rituximab (BR) and dexamethasone, rituximab and cyclophosphamide (DRC), may be considered standard-of-care for the frontline comparative studies.",
keywords = "BTK Inhibitor, Chemoimmunotherapy, Clinical trials, IgM lymphoplasmacytic lymphoma, Waldenstrom macroglobulienmia",
author = "Tam, {C. S.} and P. Kapoor and Castillo, {J. J.} and C. Buske and Ansell, {S. M.} and Branagan, {A. R.} and E. Kimby and Y. Li and Palomba, {M. L.} and L. Qiu and M. Shadman and Abeykoon, {J. P.} and S. Sarosiek and Vos, {J. M. I.} and S. Yi and D. Stephens and D. Roos-Weil and Roccaro, {A. M.} and P. Morel and Munshi, {N. C.} and Anderson, {K. C.} and J. San-Miguel and R. Garcia-Sanz and Dimopoulos, {M. A.} and Treon, {S. P.} and Kersten, {M. J.}",
note = "Funding Information: CST, MJK, PK, RGS, JSM, and SPT prepared, reviewed and submitted key questions for Consensus Panel 7 (CP7). Questions were reviewed in an open general assembly by attendants of IWWM-11, and additional questions for CP7 deliberations were formulated and submitted. CST wrote the first draft of CPT responses, and draft was reviewed and modified by MJK, PK, RGS, JSM, MA and SPT. Final draft was submitted to CP7 general panel for review and commentary. CP7 general panel was composed of individuals with experience in the care of WM patients who attended IWWM-11 and volunteered to be on CP7 panel. The authors gratefully acknowledge Beigene Pharmaceuticals, Abbvie/Pharmacyclics, Janssen Pharmaceuticals, the International Waldenstr{\"o}m Macroglobulinemia Foundation, and Cellectar Biosciences, Inc. for their support of the 11th International Workshop on Waldenstr{\"o}m Macroglobulinemia. Consensus panel reports of IWWM-11 are for educational purposes and should not be construed as offering specific medical advice for patients. Funding Information: AMR received research funding from AstraZeneca, European Hematology Association, Transcan2-ERANET, Italian Association for Cancer Research (Fondazione AIRC). Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",
year = "2023",
month = mar,
doi = "https://doi.org/10.1053/j.seminhematol.2023.03.006",
language = "English",
volume = "60",
pages = "118--124",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2",
}